Cargando…
Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma
We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the develo...
Autores principales: | Barajas, Ramon F., Pampaloni, Miguel H., Clarke, Jennifer L., Seo, Youngho, Savic, Dragana, Hawkins, Randall A., Behr, Spencer C., Chang, Susan M., Berger, Mitchel, Dillon, William P., Cha, Soonmee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352456/ https://www.ncbi.nlm.nih.gov/pubmed/25793136 http://dx.doi.org/10.1155/2015/731361 |
Ejemplares similares
-
Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine
por: Barajas, Ramon F., et al.
Publicado: (2016) -
Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications
por: Li, Yi, et al.
Publicado: (2017) -
The genetic landscape of anaplastic astrocytoma
por: Killela, Patrick J., et al.
Publicado: (2013) -
The Role of Chemotherapy in Anaplastic Astrocytoma Patients
por: Kim, Sung Kwon, et al.
Publicado: (2012) -
A rare brainstem anaplastic astrocytoma
por: You, Rongjiao, et al.
Publicado: (2022)